Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1/2 1

Status

Recruiting 4

Sponsor Class

INDUSTRY 4NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Colorectal Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 1Esophageal Neoplasms 1

Interventions

pembrolizumab 131Carboplatin 106Paclitaxel 66Cisplatin 61Gemcitabine 57Pemetrexed 56Bevacizumab 50Docetaxel 47Fluorouracil 40Oxaliplatin 38Dexamethasone 34130-nm albumin-bound paclitaxel 34Leucovorin 33atezolizumab 32Cetuximab 32durvalumab 30Nivolumab 28Rituximab 26Cyclophosphamide 26Capecitabine 26Prednisone 25Fulvestrant 24enzalutamide 23Lenalidomide 22venetoclax 21Letrozole 20Irinotecan 20Doxorubicin 17ribociclib 16pomalidomide 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Levoleucovorin × 30 days × Clear all
NCT06662786 2026-06-05

OrigAMI-2

Janssen Research & Development, LLC

Phase 3 Recruiting
1,000 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT06750094 2026-06-05

OrigAMI-3

Janssen Research & Development, LLC

Phase 3 Recruiting
700 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT05253651 2026-06-04

MOUNTAINEER-03

Seagen Inc.

Phase 3 Recruiting
400 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT06469944 2026-05-26

MK-3475-06C

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
160 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡